Transforming ideas into results
Eye on Innovation features exciting advances taking place at Mayo Clinic Laboratories. This monthly series shines a spotlight on recently developed tests, and highlights how Mayo Clinic translates ideas and discoveries into testing resources that improve diagnosis and care for patients across the globe.
As Mayo Clinic’s Anatomic Pathology moves from traditional glass slides to digital images, the advance in technology is achieving clear benefits in collaboration, learning, and patient care.
In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides answers.
Successful implementation of a new slide scanning and analysis platform across five laboratories represents a significant step forward in Mayo Clinic’s digital pathology program — an initiative that combines advanced technology with human expertise to better serve patients.
Experts at Mayo Clinic have developed a unique method of testing that combines new technology with novel bioinformatics to promptly detect a group of uncommon genetic conditions that are often difficult to identify.
To safeguard patient samples, staff in Mayo Clinic’s Histology Laboratory devised an inventive way to ensure that none of the paraffin-embedded blocks processed in the lab ever ends up in the trash.
The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.
As chair of Mayo Clinic’s new Division of Computational Pathology and AI in the Department of Laboratory Medicine and Pathology, Jason Hipp, M.D., Ph.D., is eager to employ the most innovative tools available to benefit patients around the globe.
In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity and 100% specificity. This is the first assay of its kind that can detect viral antigens “directly from clinical specimens” such as nasopharyngeal swabs. Mass spectrometry is a sensitive technique used to detect, identify, and quantitate molecules present in a sample.
A web of innovation within Mayo Clinic Laboratories links research and test development with clinical practice, enabling for some of the world’s most pioneering methodologies. Underpinning this innovation network are unique supports that provide inventive and essential solutions to broaden testing capabilities.
It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear may allow for improved recognition of this uncommon cause of Lyme disease.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.
The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.